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Guanine nucleotide exchange factors (GEFs) activate
the Rho GTPases by accelerating their GDP/GTP
exchange rate. Some RhoGEFs have been isolated
based on their oncogenic potency, and strategies
to inhibit their activity are therefore actively being
sought. In this study we devise a peptide inhibitor
screening strategy to target the GEF activity of
Tgat, an oncogenic isoform of the RhoGEF Trio,
based on random mutations of the Trio inhibitor
TRIPa, which we previously isolated using a peptide
aptamer screen. This identifies one peptide,
TRIPE32G, which specifically inhibits Tgat GEF
activity in vitro and significantly reduces Tgat-
induced RhoA activation and foci formation. Further-
more, subcutaneous injection of cells expressing
Tgat and TRIPE32G into nudemice reduces the forma-
tion of Tgat-induced tumors. Our approach thus
demonstrates that peptide aptamers are potent
inhibitors that can be used to interfere with RhoGEF
functions in vivo.
INTRODUCTION
By remodeling the actin cytoskeleton, Rho GTPases regulate
various cellular processes, such as proliferation, migration, cell
adhesion, and cell shape (Etienne-Manneville and Hall, 2002).
They are activated by the Dbl family of Rho guanine nucleotide
exchange factors (RhoGEFs), which accelerates their GDP/
GTP exchange rate (Rossman et al., 2005). RhoGEFs represent
a large family (over seventy members in mammals) of complex
proteins with numerous signaling domains, but they almost
invariably contain a functional tandem, including a Dbl homology
(DH) domain responsible for guanine nucleotide exchange,
followed by a Pleckstrin homology (PH) domain, which targets
the GEF to the plasma membrane and/or regulates nucleotide
exchange (Chhatriwala et al., 2007; Lutz et al., 2007; Rojas
et al., 2007; Rossman et al., 2003, 2005). Deregulation of RhoChemistry & Biology 16GTPase function has been associated with various human disor-
ders, including mostly cancer and metastasis, but also cardio-
vascular and hepatic disease, bacterial and viral pathogenesis,
and developmental disorders, including neurodegenerative
diseases (Sahai and Marshall, 2002; Toksoz and Merdek,
2002). Consistently, many Dbl family RhoGEFs have been
isolated based on their oncogenic potency, which often results
from a truncation of the protein, leading to uncontrolled GEF
activity and subsequent aberrant Rho GTPase activation (Eva
and Aaronson, 1985; Katzav et al., 1989; Miki et al., 1993; White-
head et al., 1995, 1996).
Rho GTPases and their GEFs therefore represent challenging
targets for inhibition, not only in terms of understanding their
function but also in pathology, and strategies to inhibit their
function are actively being sought (Bos et al., 2007). The main
issue when trying to inhibit RhoGEFs is to achieve a high
degree of specificity within such a complex and large family
of related proteins, and to target protein-protein interactions
that are not yet well characterized. To date only few strategies
have been devised successfully that have allowed for the
discovery of chemical and peptidic RhoGEF inhibitors that
block the activation of Rho GTPases by their cognate GEFs
(Blangy et al., 2006; Gao et al., 2004; Schmidt et al., 2002).
We previously described peptide aptamer screening as such
a strategy, which enabled us to discover the first RhoGEF
inhibitor (Schmidt et al., 2002). Peptide aptamers are short
peptides constrained by a bacterial thioredoxin (TrxA) scaffold,
which bind to their protein targets with high affinity (Baines and
Colas, 2006; Hoppe-Seyler et al., 2004). This technology has
been applied initially to the discovery of inhibitors against
various intracellular targets, involved mainly in cell-cycle control
or cell survival (Butz et al., 2000; Colas et al., 1996; Crnkovic-
Mertens et al., 2003; Fabbrizio et al., 1999; Martel et al.,
2006; Nouvion et al., 2007). Peptide aptamers present inter-
esting advantages over other classes of inhibitory molecules,
mainly because of their simple design and their high degree
of binding specificity, which enables them to discriminate
between closely related proteins within a functional family.
But most remarkably, these highly combinatorial proteins are
screened and designed to function inside living cells and allow
the study of protein function within complex regulatory, 391–400, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 391
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Targeting Tgat Oncogene with Peptidic InhibitorsFigure 1. The Transforming Activity of Tgat Requires its GEF Activity
toward RhoA
(A) Schematic representation of Trio and its splice variant Tgat, and the Tgat
mutant used in this study.
(B) RhoA activation assay. Lysates of NIH 3T3 cells stably expressing GFP,
GFP-Tgat, or GFP-TgatL190E were subjected to GST pull down using recombi-
nant RBD (RhoA-binding domain of rhotekin). The levels of GTP-bound RhoA
(top panel) and total RhoA protein (middle panel) were assessed by western
blot with a monoclonal anti-RhoA antibody. All GEF constructs were
expressed at a similar level as shown by western blotting using an anti-GFP
antibody (lower panel).
(C) Quantification of the RhoA activation assay from at least three independent
experiments. ‘‘Fold RhoA activation’’ means the amount of RhoA-GTP in the
sample, as compared with the amount in the GFP control, which was set to 1.
(D) Focus formation assay of NIH 3T3 cells stably expressing GFP, GFP-Tgat,
GFP-TgatL190E, or GFP-Trio.
(E) Quantification of three independent focus formation assays. The number of
foci induced by Tgat was set to 100%. Error bars represent standard deviation
in all graphs.networks (Bickle et al., 2006). The RhoGEF inhibitor we have
isolated using this aptamer screening strategy, called TRIPa
(Trio inhibitory peptide a), targets specifically the DH2-PH2
tandem of the RhoGEF Trio and inhibits its activation of RhoA
both in vitro and in intact cells, reverting the neurite retraction
phenotype induced by Trio DH2-PH2 in PC12 cells (Schmidt
et al., 2002). Most interestingly, although TRIPa was initially
selected with the TrxA scaffold, it remained equally active as
a linear peptide (Schmidt et al., 2002).
The recently identified oncogenic RhoGEF Tgat is an inter-
esting novel candidate target for such peptidic inhibitors.
Indeed, Tgat has been identified from adult T cell leukemia
(ATL) patient cells as a gene with oncogenic potency and origi-392 Chemistry & Biology 16, 391–400, April 24, 2009 ª2009 Elseviernates from an alternate splicing of the trio gene (hence the
name Tgat, for Trio-related transforming gene inATL tumor cells)
(Yoshizuka et al., 2004). Tgat retains only the RhoA-specific DH2
domain of Trio and, instead of the associated PH2 domain,
carries a unique C-terminal sequence of 15 amino acids. It
induces cell transformation and tumor formation in nude mice
(Yoshizuka et al., 2004) and has been proposed to enhance
tumor invasion by stimulating matrix metalloproteinases
(MMPs) via the RECK protein (Mori et al., 2007) and by activating
the transcription factor NF-kB, which plays a crucial role in
tumorigenesis, including ATL (Yamada et al., 2007).
In this context, designing peptide inhibitors against the
RhoGEF Tgat is very challenging, not only from a pathological
point of view, but also from a conceptual perspective, ad-
dressing the important issue of specificity when targeting
proteins that, like RhoGEFs, belong to families with high
homologies.
In this study we devised an optimization screen based on the
TRIPa peptide, which allowed us to identify a novel peptide that
is active as a Tgat inhibitor, targeting its GEF activity in vitro in
a highly specific manner. Moreover, it strongly reduces its onco-
genic properties in vivo, most remarkably by decreasing foci
formation and tumor development in nude mice. Our peptide
optimization strategy identifies the first inhibitor of the Tgat
oncogene, and demonstrates that aptamers can be used to
interfere with RhoGEF functions in vivo with exquisite speci-
ficity.
RESULTS
The GEF Activity of the DH Domain Is Required
for Tgat-Induced Transformation
In order to design inhibitors that would target Tgat oncogenic
activity, we first established whether the GEF activity of Tgat
is involved in transformation. To do so, we designed a Tgat
mutant, called TgatL190E, which harbors a point mutation in its
DH domain, the equivalent mutation in Trio DH2-PH2 being
known to abolish its exchange activity on RhoA (Figure 1A)
(Bellanger et al., 2003). We established NIH 3T3 cell lines stably
expressing similar levels of GFP or GFP-tagged Tgat or
TgatL190E (Figure 1B, lower panel), and analyzed the ability of
these constructs to activate RhoA and to induce transforma-
tion. We measured RhoA activation in intact cells by pull
down of RhoA-GTP, using the RhoA-binding domain (RBD) of
its effector rhotekin fused to glutathione S-transferase (GST)
(Figures 1B and 1C). Tgat strongly stimulated RhoA activation
(8-fold over control), whereas the GEF-impairing mutation
completely abolished the formation RhoA-GTP in cells. We
then tested the oncogenic properties of the different Tgat
constructs, by scoring the formation of foci in the different
cell lines (Figures 1D and 1E). Although Tgat-expressing cells
formed numerous foci, TgatL190E-expressing cells presented
no foci after 3 weeks in culture, showing that the GEF activity
of the DH domain is required for the transforming potential of
Tgat. In addition, NIH 3T3 cells stably expressing full-length
Trio did not exhibit any foci, showing that the transforming
potential is not inherent to Trio but only to its oncogenic isoform
Tgat (Figures 1D and 1E).Ltd All rights reserved
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Because the GEF activity of Tgat is necessary for transforma-
tion, molecules that block this biochemical activity could also
inhibit its transforming potential. We previously identified
a peptide aptamer, TRIPa, which targets the RhoA-specific
DH2-PH2 tandem of Trio (Schmidt et al., 2002). Because Tgat
harbors the DH2 domain of Trio, we tested whether Tgat
activity was also inhibited by TRIPa. However, to our surprise,
when tested in a [3H]-GDP dissociation inhibition assay in vitro,
TRIPa was only a weak inhibitor of Tgat (Kiapp = 89 ± 33 mM;
see below).
We thus sought to optimize TRIPa inhibition efficiency by first
determining which amino acids are essential for its inhibition. By
using an Ala-Scan analysis, each residue of the active core of
TRIPa (amino acids 9–36; Schmidt et al., 2002) was mutated to
alanine except cysteines, which were changed into serines. All
TRIPa mutants were then tested for their inhibitory activity on
Trio DH2-PH2 in [3H]-GDP dissociation assays. This analysis
mapped two essential regions of TRIPa, amino acids 9–20 and
28–33, where single mutations were sufficient to impair inhibition
(Figure 2A). However, none of the mutants exhibited stronger
inhibition toward Trio DH2-PH2 and were not further investigated
on Tgat.
We next reasoned that peptides that would bind stronger to
the GEF domain might also be better at inhibiting its activity.
We thus generated a library of peptide aptamers derived from
TRIPa by random mutagenesis, which we screened for GEF
binding in a yeast two-hybrid assay. We chose a system in which
the threshold of interaction detection can be modulated by the
concentration of the 3-aminotriazole (3-AT) drug (Sardet et al.,
1995). Because Tgat is toxic in yeast, we used Trio DH2-PH2
to screen this TRIP-like peptide library. Thirty-five independent
clones bound to Trio DH2-PH2 at concentrations of 3-AT at
which no interaction with TRIPa was detected anymore (80–
120 mM). These clones were then produced as GST-fusions
and analyzed for their inhibition of Trio DH2-PH2, using the
[3H]-GDP dissociation assay. As shown in Figure 2B, ten of
them were stronger inhibitors than TRIPa. Analysis of their
sequence revealed that they contained one to four mutations
per peptide, and that, consistently, most of them resided within
the two regions identified as crucial for the inhibitory properties
of TRIPa (Figure 2B, shaded residues).
We then analyzed the inhibitory activity toward Tgat of
TRIPE32G and TRIPT16M/L17S, the two TRIP-like peptides that dis-
played the highest inhibition on Trio DH2-PH2 (Figure 2B).
Both peptides inhibited Tgat GEF activity in a dose-dependent
manner in a kinetics fluorescence assay, whereas GST alone
(not shown) or GST-TRIPa, at the same concentrations, had no
effect (Figure 2C). Accordingly, the apparent inhibition constant
(Kiapp) of TRIPa toward Tgat was 89 ± 33 mM, and decreased
to 7.4 ± 5 mM for TRIPE32G and 5.1 ± 4 mM for TRIPT16M/L17S
(Figure 2D). These data show that TRIPE32G and TRIPT16M/L17S
are both about 15 times more efficient than TRIPa at inhibiting
the exchange activity of Tgat.
Interestingly, the optimized peptides were equally efficient on
Tgat and on Trio DH2, as shown by their similar Kiapp values
(Figures 2C and 2D). This suggests that the unique C-terminal
extension of Tgat is not involved in the inhibitory mechanism of
the optimized peptides, and is consistent with the fact that thisChemistry & Biology 16sequence does not interfere with the GEF activity in vitro (data
not shown).
Inhibition by TRIP Peptides Is Specific for Tgat
We then analyzed the specificity of the optimized TRIP peptides
by testing their inhibitory properties on other related RhoGEFs.
We had shown previously that TRIPa is not active on the
RhoA-specific GEFs p115RhoGEF, Lbc, p63RhoGEF, or Dbl
(Schmidt et al., 2002 and unpublished data). Similarly, when
tested in mant-GTP fluorescence kinetics at a concentration
at which Tgat is fully inhibited, TRIPE32G and TRIPT16M/L17S had
no effect on the exchange activities of these closely related
RhoGEF/Rho-GTPase tandems, p115RhoGEF/RhoA, Lbc/
RhoA, Dbl/RhoA, and even the very closely Trio-related p63Rho-
GEF/RhoA (70% identity within the DH-PH module), or Trio DH1-
PH1/RhoG (40% identity with Tgat) (Figure 3). Taken together,
these data show that the optimized TRIP peptides are highly
specific for Tgat and Trio DH2.
TRIPE32G Inhibits the Transforming Activity
of Tgat In Vivo
We next analyzed whether our TRIP-like peptides inhibited
Tgat-mediated RhoA activation in intact cells. For that purpose,
NIH 3T3 cells stably expressing Tgat were transfected with the
GFP-tagged TRIP-like peptides or GFP alone, and RhoA activa-
tion levels were assessed by the GST-RBD pull-down assay
(Figure 4). Although TRIPE32G and TRIPT16M/L17S inhibited the
in vitro GEF activity of Tgat to a similar extent, TRIPE32G was
more efficient than TRIPT16M/L17S at inhibiting Tgat-mediated
activation of RhoA in cells (Figures 4A and 4B). These data
show that, in addition to its effect on in vitro guanine nucleotide
exchange, TRIPE32G inhibits Tgat GEF activity also in intact
cells.
In order to verify the exquisite specificity of our peptide toward
Tgat/DH2 in vivo, we analyzed by GST-RBD pull-down assay
whether TRIPE32G could inhibit oncogenic Dbl-mediated RhoA
activation in intact cells. Figure 4C shows that, in contrast to its
effect on Tgat activity, TRIPE32G was not able to inhibit RhoA
activation by Dbl, confirming the in vitro specificity of TRIPE32G
toward Tgat.
We then investigated whether TRIPE32G was able to inhibit
Tgat-induced transformation. To do so, we stably expressed
GST or GST-TRIPE32G in Tgat-expressing NIH 3T3 cells and char-
acterized their transforming potential. After 3 weeks of culture,
the foci present in Tgat-expressing cells were severely reduced
when coexpressing TRIPE32G (Figures 5A and 5B). This reduction
is not due to a nonspecific effect of TRIPE32G on cell proliferation
or apoptosis (data not shown). These data show that targeting
Tgat GEF activity with TRIPE32G is sufficient to impair Tgat trans-
forming activity.
To further establish the inhibitory effect of TRIPE32G on Tgat
transforming activity in vivo, we subcutaneously inoculated
Balb/c nude mice with NIH 3T3 cells expressing either Tgat or
Tgat and TRIPE32G, and analyzed their effect on tumor formation.
Tgat-transformed cells produced tumors in 10 of 12 mice.
Remarkably, when TRIPE32G was coexpressed with Tgat, only
7 mice had tumors, and we observed a delay of about 3 weeks
in the formation of tumors (Figure 5C). In addition, even though
tumor formation was not abolished, the weight of the tumors, 391–400, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 393
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Targeting Tgat Oncogene with Peptidic InhibitorsFigure 2. Identification and Characterization of Optimized Inhibitory TRIP-like Peptides
(A) Alanine-scanning of the active core of TRIPa. Inhibition efficiency of the mutated peptides was measured by [3H]-GDP dissociation assays using Trio DH2-
PH2, and compared with the original TRIPa peptide. Black bold letters indicate residues strictly required for inhibition, whereas gray bold letters represent resi-
dues retaining a weak inhibitory potential. All the other residues are nonessential. Shaded residues are regions (aa 9–20 and 28–33) that emerge as being essential
for TRIPa activity.
(B) Amino acid sequence of the optimized TRIP-like peptides, obtained by random mutagenesis of the original TRIPa peptide. Inhibition efficiency was measured
on Trio DH2-PH2 and compared with TRIPa, as described in (A). ‘‘Fold over TRIPa inhibition’’ means stronger inhibition at the same inhibitor concentration (inhi-
bition by TRIPa was set to 1).
(C) Inhibition of Tgat GEF activity by TRIPT16M/L17S and TRIPE32G in vitro. FRET fluorescence exchange assays were performed using constant concentrations of
RhoA (1 mM), equal amounts (0.5 mM) of Tgat (left panel) or Trio DH2 (right panel), and increasing concentrations of GST-TRIP peptides, up to 100 mM. Results
were expressed as kobs values plotted as a function of the indicated TRIP inhibitor concentration.
(D) Apparent inhibition constants (Kiapp) of the TRIP peptides for Tgat and Trio DH2, as indicated. The values and error bars are calculated from at least three
independent experiments. Error bars represent standard deviation.394 Chemistry & Biology 16, 391–400, April 24, 2009 ª2009 Elsevier Ltd All rights reserved
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Targeting Tgat Oncogene with Peptidic Inhibitorswas significantly reduced when TRIPE32G was expressed
(Figure 5D). Altogether, these data show that expression of
TRIPE32G strongly reduces Tgat transformation activity in cells
and affects tumor formation in nude mice, most likely by inhibit-
ing Tgat-mediated GTP loading of RhoA.
DISCUSSION
Peptide Aptamers as New Inhibitors of RhoGEFs
Because of their deregulation in many human disorders
including cancer, Rho GTPases and their activating GEFs
represent challenging targets for inhibition. In humans there
are only 20 Rho GTPases but more than 70 RhoGEFs, and it
appears that signaling specificity is mostly determined by the
GEFs, which activate the GTPases at defined timing and loca-
Figure 3. Specificity of the Optimized
Inhibitory TRIP Peptides
Comparison of TRIPE32G and TRIPT16M/L17S inhibi-
tion efficiency on different GTPase/RhoGEF
systems, using 1 mM GTPase and 0.5 mM GEF
(except for Dbl and Trio DH1PH1, where 0.1 mM
GEF was used): (A) RhoA/Tgat; (B) RhoA/p63Rho-
GEF; (C) RhoA/p115RhoGEF; (D) RhoA/Lbc; (E)
RhoA/Dbl; (F) RhoG/Trio DH1PH1. In each assay,
the peptides were used at a concentration of
20 mM, corresponding to a 40-fold molar excess
of inhibitor versus GEF. All fluorescence kinetics
assays were performed using 1 mM mant-GTP.
Results are expressed as relative fluorescence
units (RFU) versus time. The reaction performed
in the absence of GEF reflects the spontaneous
exchange activity of the GTPase.
tion. RhoGEF inhibitors therefore repre-
sent an emerging field of investigation.
Here we developed a peptide aptamer
screening strategy to inhibit the RhoGEF
Tgat, a potential target in ATL. Because
Tgat is an isoform of the RhoGEF Trio,
which includes the RhoA-specific DH2
domain plus a unique C-terminal
sequence, we based our screen on our
previously identified Trio inhibitor TRIPa,
the first peptidic RhoGEF inhibitor
described, which targets the DH2-PH2
domain of Trio (Schmidt et al., 2002).
Intriguingly, although Tgat harbors the
Trio DH2 domain, our original TRIPa inhib-
itor was rather ineffective at inhibiting
Tgat. This suggests that the PH2 domain
of Trio is involved in the mechanism of
action of TRIPa, and that its replacement
by the C-terminal extension decreases
TRIPa’s ability to inhibit the GEF activity
of Tgat.
We show here that GEF inhibitors
selected with the peptide aptamer
screening approach are readily amenable to structure-activity
relationship analysis and optimization. Of the 28 residues
located in the active core of TRIPa, alanine scanning mapped
9 residues in two regions (residues 9–20 and 28–33) that were
critical for the catalytic activity, whereas 6 had a moderate
effect and the others had no effect. We also show that peptide
aptamer optimization can be achieved by random mutagenesis
combined with a selection screen based on interaction
strength. At least one third of the isolated clones yielded
stronger inhibition, thus validating the rationale of the screen.
The two selected peptides, TRIPE32G and TRIPT16M/L17S, were
15-fold more efficient than TRIPa and inhibited Tgat GEF
activity at concentrations lying in the low micromolar range.
Interestingly, mutations found in these clones also fell within
the two important regions identified by the Ala-scan. Further-
more, this approach allowed us to turn TRIPa into a TgatChemistry & Biology 16, 391–400, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 395
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Targeting Tgat Oncogene with Peptidic InhibitorsFigure 4. TRIPE32G Inhibits Tgat GEF Activity in Cells
RhoA activation in NIH 3T3-Tgat cells transiently transfected with GFP, GFP-
TRIPE32G or GFP-TRIPT16M/L17S was assayed by the GST-RBD-pull-down
assay as described in Figure 1B.
(A) The levels of GTP-bound and total RhoA protein are shown in the upper two
panels. Expression levels of all GFP-tagged proteins are shown in the lower
panel.
(B) Quantification of the RhoA activity assay from at least three independent
experiments. Error bars represent standard deviation.
(C) Effect of GFP-TRIPE32G on RhoA activation induced by Dbl (left panel) or
Tgat (right panel) in NIH 3T3 cells, assayed by GST-RBD pull down. The levels
of GTP-bound and total RhoA protein are shown in the upper two panels.
Expression levels of Myc-Dbl and of all GFP-tagged proteins are shown in
the lower two panels.inhibitor, which could be achieved with as few as one mutation,
E32G. It remains to be determined whether these different
amino acids are important for binding to the GEF and/or for inhi-
bition of the exchange reaction.
It should be emphasized that our screening and optimization
method is effective, irrespective of the inhibitory mechanism,
which is of big advantage for the discovery of inhibitors of
protein-protein interactions. The way the original screen was
performed, i.e., two-hybrid screening with the GEF as bait in
the absence of GTPase, strongly suggests that the target of
the peptides is the GEF itself, rather than the GTPase. This is re-
inforced by the fact that the peptides do not inhibit spontaneous
GDP release from RhoA using [3H]-GDP-loaded RhoA (data not
shown), and by our specificity data in vitro and in intact cells,
which show that other GEF activities toward RhoA are not
inhibited (Figures 3 and 4). At this stage we cannot, however,
distinguish between competitive and allosteric inhibition, or
even a less likely uncompetitive mechanism.
Remarkably, the characterization of our optimized TRIP
peptides clearly shows that gain of efficiency is not asso-
ciated with loss of specificity. Indeed, none of the RhoA-acti-396 Chemistry & Biology 16, 391–400, April 24, 2009 ª2009 ElsevierFigure 5. TRIPE32G Inhibits the Transforming Activity of Tgat In Vivo
(A) Focus formation assay of NIH 3T3 cells, stably expressing GFP or GFP-
Tgat, together with GST or GST-TRIPE32G.
(B) Quantification of three independent focus formation assays. The number of
foci formed by Tgat/GST expressing cells was set to 100%.
(C) Tumor formation in Balb/c nude mice. NIH 3T3 cells stably expressing GFP-
Tgat/GST or GFP-Tgat/GST-TRIPE32G were injected subcutaneously into the
flanks of Balb/c nude mice and tumor volume was measured every week.
The graph is representative of the three independent assays that were per-
formed.
(D) Ten weeks after the graft, mice were killed, tumors were excised and
weighed, and the mean tumor weight was plotted.
*A paired Student’s t test was performed, matching the samples for each
mouse (p = 0.019). Error bars represent standard deviation in all graphs.vating GEFs we tested, in particular the very closely related
p63RhoGEF, were affected by either TRIPE32G or TRIPT16M/L17S.
In addition, the TRIP peptides did not affect the activity of GEFs
with different specificity such as the RhoG/Rac1-specific
TrioDH1-PH1.
Peptide Aptamers Are Functional In Vivo
Our screening method demonstrates that TRIPE32G is not only
effective and specific at inhibiting Tgat GEF activity in vitro,
but that it also blocks Tgat-induced cell transformation and
tumor formation in vivo. This is the first example of a peptidic
RhoGEF inhibitor that is functional in vivo, and demonstrates
that aptamers can be used as active peptides to perturb
the function of GEFs in vivo. In this context, efficient in vivo
delivery is a critical issue when working with peptides. To
circumvent this problem, the use of recently developed cell-
penetrating peptides represents a good means of delivery
for TRIPE32G, and could be an attractive strategy to investi-
gate the contribution of Tgat in leukemogenesis. Indeed, to
date, the incidence of Tgat in ATL leukemogenesis isLtd All rights reserved
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tion and transformation, we can hypothesize that Tgat is
involved in the progression of ATL by contributing to RhoA-
mediated proliferation and/or metastasis. Our series of TRIP
peptides should now provide useful tools to decipher the
cellular role of Tgat.
Peptide Aptamers versus Other GEF
Inhibitor Screening Strategies
Besides our peptide aptamer screening approach, other strate-
gies have recently been devised to discover chemical inhibitors
of Rho GTPase/GEF tandems, and also other classes of small G
proteins, such as the Arf family and their activating GEFs (Blangy
et al., 2006; Desire et al., 2005; Gao et al., 2004; Mayer et al.,
2001; Shutes et al., 2007; Viaud et al., 2007). Computer-assisted
virtual screening, for example, identified the NSC23766
compound, based on structure-function information of the
Rac1/Tiam1 complex. This powerful molecule inhibits specifi-
cally Rac1-induced events in vitro and in vivo, but the targeted
associated RhoGEFs include at least Tiam1 and Trio DH1-PH1
(Gao et al., 2004). In silico screening also yielded the LM11
compound, which inhibits specifically the ARNO/Arf1 interface
in vitro and is active in cells (Viaud et al., 2007). Given their
membrane permeability, both NSC23766 and LM11 have the
advantage of being easily applied in vivo.
The yeast exchange assay is another screening method that
allowed the identification of the TrioDH1-PH1-specific NPPD
compound and its analogs (Blangy et al., 2006). Like peptide
aptamer screening, this strategy has the advantage over virtual
screening of identifying inhibitors directly in cells, and without
any bias as to the targeted interaction site.
Finally, in vitro RNA-aptamer screening selected the RNA
aptamer M69 as an inhibitor of the cytohesin/Arf1 tandem
(Mayer et al., 2001). Like peptide aptamers, these RNA aptamers
are highly combinatorial and easily screened, but their applica-
tion as potential drugs remains limited, due to difficult in vivo
delivery. To circumvent this problem, RNA-aptamer displace-
ment represents an elegant method, in which a small-molecule
library is screened for compounds that displace the RNA ap-
tamer from its target and reproduce its inhibitory activity (Hafner
et al., 2006).
Our study shows that peptide aptamer screening represents
a valid strategy for inhibitor identification that can be applied to
a variety of different proteins, because of the in vivo screening
method and the highly combinatorial libraries available, yielding
strong affinity inhibitors. This is illustrated here by the identifica-
tion of a highly specific peptidic RhoGEF inhibitor targeting the
Tgat oncogene in vitro and in vivo.
SIGNIFICANCE
When trying to inhibit signaling pathways controlled by small
G proteins and their activating GEFs, the challenge is that
these are not mere enzymes with a well-defined active site
that can be blocked. Rather, protein-protein interactions
have to be targeted and the lack of reactive pockets towhich
inhibitors could bind is a challenging issue. Thismight in part
explain why, although oncogenic Ras has been discoveredChemistry & Biology 16,more than 20 years ago, no inhibitor with clinical validation
has been identified. Therefore, research has focused on
trying to inhibit the guanine nucleotide exchange factors
instead, and recent studies report the successful identifica-
tion of such inhibitors.
The power of the strategy we used here to identify the
TRIP peptides relies on the screening of a highly combinato-
rial aptamer library, generating immense possibilities of
random peptides. This variety makes peptide aptamers
very suitable molecules to inhibit complex protein-protein
interactions such as the tandem RhoGEF/GTPase, and to
discriminate between closely related proteins. One major
advantage of this kind of approach is that the screening is
cell based, which gives a direct readout for toxicity and is
more stringent. Moreover, peptide aptamers do not mimic
cellular targets, which could have undesired effects in cells.
In addition, to circumvent the problem of in vivo delivery
when using peptide aptamers, aptamer-displacement
screens can be performed to convert an aptamer into
a small-compound inhibitor (Baines and Colas, 2006). The
advantage is that the corresponding compound targets the
same site and shares the same properties as the already
characterized peptide.
In conclusion, peptide aptamers represent a promising




Tgat (amino acids [aa] 1–255) was designed by ligating dimerized oligonucle-
otides coding for the specific C terminus of Tgat (15 aa) to the Trio DH2 domain
(residues 1862–2101, corresponding to aa 1–240). The oligonucleotide
sequences are available upon request. The TgatL190E mutant was obtained
using the QuikChange Site-Directed Mutagenesis Kit (Stratagene), according
to the manufacturer’s instructions.
To create stable NIH 3T3 cell lines, GFP-tagged Tgat, TgatL190E, and
full-length Trio were cloned into the puromycin-resistant retroviral vector
pBabePuro. GST-tagged TRIP peptides were cloned into the G418-resistant
retroviral vector pLXSN. For transient transfections, both Tgat and TRIP
peptides were cloned into the pEGFP vector (Clontech). Myc-Dbl was
a kind gift of Michael Olson (Beatson Institute for Cancer Research, Glas-
gow). For in vitro GEF assays, Tgat (aa 1–255) was fused to maltose-
binding protein (MBP) by cloning into a modified pMAL C2X vector (New
England Biolabs). The TRIP peptides were fused to GST by cloning into
the pGEX-5X2 vector (GE Healthcare). All constructs were checked by
sequencing.
Expression and Purification of Recombinant Proteins
Tgat and DH2
MBP-Tgat and MBP-DH2 expression in E. coli was induced for 24 hr at
16C with 0.1 mM isopropylthio-galactopyranoside. After cell lysis (in
50 mM Tris [pH 7.5], 1 mM EDTA, 2 mM MgCl2, 1 mM DTT), the suspension
was centrifuged at 10,000 3 g for 20 min, then at 400,000 3 g for 1 hr
30 min. The supernatant was applied to a Q-Sepharose column fast flow
(GE Healthcare) equilibrated with lysis buffer. The protein was eluted with
a linear gradient of 0.250 mM NaCl in 50 mM Tris (pH 7.5). Fractions con-
taining the protein were adjusted to a concentration of 2 M NaCl and loaded
on a Phenyl sepharose Fast Flow High Sub (GE Healthcare). The protein was
eluted with a linear gradient of 2.0 M NaCl in 50 mM Tris (pH 7.5). The puri-
fied proteins were concentrated on a Vivaspin concentrator (Vivascience
AG) at 18 mg/ml.391–400, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 397
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Recombinant GST-Trio DH2-PH2, GST-Trio DH1-PH1, GST-Dbl (DH-PH
domain), GST-Lbc (DH-PH), GST-p63RhoGEF (DH domain), and GST-RhoG
were purified as described previously (Schmidt et al., 2002; Souchet et al.,
2002). Expression and purification of GST-p115RhoGEF using the baculo virus
system will be described elsewhere.
GST-Peptides
GST-TRIP peptides were purified as described previously (Schmidt et al.,
2002), except that the cell lysate was centrifuged as above, before loading
on a GSTrap Fast Flow column (GE Healthcare) equilibrated with lysis buffer.
Peptides were eluted with reduced glutathione (10 mM) in Tris 50 mM
(pH 7.5) and concentrated on Vivaspin concentrator at about 5–10 mg/ml.
Optimization of TRIPa
Alanine Scanning of TRIPa
Every amino acid of the active core of TRIPa (amino acids 9–36) was mutated
to alanine (or serine for cysteine residues) by site-directed mutagenesis of
GST-TRIPa. Each TRIPa mutant was tested for its inhibitory activity on DH2-
PH2 in [3H]-GDP dissociation assays.
Two-Hybrid Screening of TRIPa-Like Peptides
An aptamer library derived from TRIPawas created by polymerase chain reac-
tion (PCR)-based random mutagenesis of TRIPa inserted into the yeast two-
hybrid vector pPC86. Sequencing of a statistically representative number of
clones yielded a mutation rate of about three mutations per clone. A total of
6 3 105 independent clones were screened for interactors by using Trio
DH2-PH2 (in the pPC97 vector) as a bait, in the MAV103 yeast strain, on
high concentrations of 3-AT (80–120 mM, Sigma). Selected peptides were
then produced as GST fusions and analyzed for their inhibition of Trio DH2-
PH2 using the [3H]-GDP dissociation assay.
Nucleotide Exchange Kinetics Assay
Specific exchange rates of Tgat were measured with a fluorescence-based
kinetics assay, using a 6His-RhoA construct (gift of Dr. Derewenda, Charlot-
tesville University, Charlottesville, VA) purified as described (Oleksy et al.,
2004). Exchange activities were followed by fluorescence resonance energy
transfer (FRET) between the GTPase tryptophanes (lex = 292nm) and the
methylanthranyloil group of mant-GTP (lem = 440nm) as described previously
(Zeeh et al., 2006). All fluorescence measurements were performed with
a CARY Eclipse fluorimeter (Varian). For each kobs determination, RhoA
(1 mM) and Tgat (or Trio DH2) were preincubated for 3 min at 25C in 700 ml
reaction buffer (50 mM Tris [pH 7.5], 50 mM NaCl, 2 mM MgCl2, 1 mM DTT).
The exchange reaction was initiated by 10 mM mant-GTP and measured for
10 min until the plateau was reached.
kobs were calculated by fitting the FRET fluorescence changes to a single
exponential, using Kaleidagraph software. Specific exchange activities were
calculated by linear regression of kobs values determined for a range of GEF
concentrations (0, 0.2, 0.3, 0.4, 0.5, and 1 mM).
Nucleotide Exchange Inhibition Assays
Radioactive [3H]-GDP dissociation assays were performed as described
previously (Schmidt et al., 2002). Briefly, 0.15 mM GST-Trio DH2-PH2 was
preincubated for 15 min with 3 mM GST-TRIP inhibitors. The reaction was
started by addition of 0.4 mM [3H]-GDP-loaded RhoA and 1 mM GTP, and
the reaction mix was filtered after 0 min and 15 min incubation at 25C. Inhi-
bition efficiency is expressed as the ratio between [3H]-GDP-bound RhoA at
15 and 0 min.
Apparent inhibition constants (Kiapp) of TRIP-like peptides were determined
from kobs values obtained at increasing peptide concentrations using the
above fluorescence nucleotide exchange assay. Kiapp was calculated from
the hyperbolic fit of kobs values as a function of the inhibitor concentration as
described (Zeeh et al., 2006).
TRIP-like peptide specificity was assayed using mant-GTP fluorescence
kinetics (lex = 360 nm, lem = 460 nm) in a FLX800 Microplate Fluorescence
Reader (BioTek Instruments). 0.5 mM Tgat, p63RhoGEF, Lbc, and p115Rho-
GEF, or 0.1 mM Dbl and Trio DH1-PH1 were preincubated for 5 min at 25C
in the presence of 20 mM GST, GST-TRIPE32G, or TRIPT16M/L17S and 1mM398 Chemistry & Biology 16, 391–400, April 24, 2009 ª2009 Elseviermant-GTP. The exchange reaction was initiated by addition of 1 mM RhoA or
RhoG and monitored for 10 min.
Cell Lines, Transfection, and Focus Formation Assay
NIH 3T3 cells were maintained as described previously (Sirvent et al., 2007).
Transient transfection experiments were performed using the Jet PEI
reagent, according to the manufacturer’s protocol (QBiogene). NIH 3T3 cell
lines stably expressing GFP-Tgat, GFP-TgatL190E, or GFP-Trio, with or
without the GST-TRIP peptides, were generated as follows: the indicated
retroviral constructs were transfected into BOSC packaging cells, using
the Lipofectamine reagent (Invitrogen). Forty-eight hours after transfection,
virus-containing supernatants were collected and used to infect NIH 3T3
cells. Infected cells were selected with 6 mg/ml puromycin and/or 1 mg/ml
G418, and stable transfectants were pooled after selection. Tgat or TRIP
mRNA levels in the different cell lines were monitored by RT-PCR, and
protein expression levels by western blot analysis using a polyclonal anti-
GFP antibody (Torrey Pines Laboratories).
Focus formation assays were performed using stable NIH 3T3 cell lines as
indicated, seeded at 5 3 104 cells in 6-well plates and maintained for 15 to
21 days in 10% fetal bovine serum. Medium was renewed every 2 days.
After staining with crystal violet (1%), plates were photographed and foci
were scored using Metamorph software. All experiments were done in trip-
licate.
RhoA Activation Assay in Cells
The level of GTP-bound RhoA was measured by a GST pull-down assay
as described elsewhere (Schmidt et al., 2002). Briefly, cell lysates were
incubated with glutathione beads coated with the recombinant Rho-
binding domain (RBD) of the RhoA-specific effector rhotekin (Cytoskel-
eton). Total or GTP-bound RhoA in the samples was revealed by western
blot analysis, using a monoclonal anti-RhoA antibody (Santa Cruz Biotech-
nology).
Mice and Xenografting
Female Balb/c nu/nu mice were purchased from Charles River France and
used at 6–8 weeks of age. Twelve Balb/c nu/nu mice were subcutaneously
grafted with 2 3 106 cells of each cell line on both sides (Tgat on the left and
Tgat+TRIPE32G on the right flank of the leg). The appearance of tumors was
scored visually every week. Ten weeks after the graft, mice were killed and
tumors were excised and weighed. mRNA and protein levels in the tumors
were verified by RT-PCR and western blot (data not shown). All experiments
on mice were approved by the internal ethical committee of the IRCM and
performed by B.R. under authorization number N 34.156, in the animal facility
with agreement N B34-172-27.
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